OneSource’s Full Capacity and Canada Semaglutide Drive FY28 Confidence

OneSource Specialty Pharma Limited — Q1 FY27 Earnings Call (held July 25, 2026; results for quarter ended June 30, 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly emphasizes “fairly strong” quarter, “meaningful step up” in Canada semaglutide commercialization, and “remain confident” while reiterating FY28 targets.
• Uses strong demand/capacity language: “available capacities are full”, “order book is very clear”, “pipeline… almost 4x”.

2. Key Themes from Management Commentary

• Semaglutide commercialization momentum (DDC/drug-device combination):
• Revenue growth attributed to “semaglutide commercial launch” plus “new MSA contracts” and “new customer wins”.
• Canada highlighted as a key driver: “all three approvals… are with us” and “two of our partners… have already launched”.
• India highlighted as supply-constrained historically: “more than 40% of the generic pens sold in India are manufactured at our site”.
• Capacity expansion now translating into operational flexibility:
• First phase of $100m capex nearing fruition; “second cartridge line being set for commercialization in this quarter” and will “double… sterile days”.
• Management claims prior customer onboarding constraints are easing: “we would be adding customers… process has already begun”.
• Lines described as fungible across customers/products; batch size increases (200L → 500L) to improve output per sterile day.
• Biologics build-out as a long-duration growth pillar:
• “added yet another marquee global biotech major” via Formycon partnership.
• “pipeline… almost 4x” vs ~1 year ago; described as “strongest ever” and “sticky”.
• Management expects biologics to contribute beyond FY28 due to long gestation.
• Soft gelatin and injectables:
• Soft gel capacity expansion framed as transitioning from captive/IP-led to CDMO services; tech transfers taking time.
• Injectables framed as scarcity/shortage play (penicillin, FDA shortage list) plus new capabilities (prefilled syringes, lyophilization).
• Compliance as a competitive moat:
• “12 successful inspections… including two surprise FDA audits” and “compliance track record remains exemplary”.
• Macro/geopolitics addressed as manageable:
• Freight disruption from Middle East issues acknowledged, but management says impact is “fairly muted” due to ex-works contracts.

3. Q&A Analysis

Theme A: Soft gelatin growth lag vs capacity build-out

• Core question(s):
• Why soft gel revenue didn’t scale as expected despite capacity rising (800m → 2.4b)?
• Whether group issues in ibuprofen are impacting soft gel.
• Management response:
• Soft gel historically “captive IP-led products” under Strides; now adding CDMO services requires tech transfers and time.
• Capacity expected to be “completely taken over the next 12 to 15 odd months”.
• No direct mention of ibuprofen impact; instead emphasizes customer onboarding and tech transfer timelines.
• Also mentions starting a greenfield because current site can’t expand further.
• Assessment (evasive/partial/strong):
• Partially evasive on ibuprofen linkage (no clear “yes/no”); explanation focuses on tech transfer and customer conversion timing.

Theme B: Sterile injectable line shutdown timing and margin drivers

• Core question(s):
• Does the planned plant shutdown impact Q1 or only Q2?
• What explains sequential margin improvement (mix vs overheads)?
• Management response:
• Shutdown starts in Q1; “Q2… will be the quarter” and lasts into next quarter.
• Margin improvement attributed mainly to mix:
  • Higher contribution from drug-device combination.
  • H2-heavy seasonality for soft gel/injectables.
• Overheads not highlighted as the driver; emphasis on contribution/mix.
• Assessment:
• Clear and fairly direct on shutdown timing; mix explanation is plausible but still high-level (no quantified overhead/mix bridge).

Theme C: Customer supply disruption risk (Dr. Reddy’s) and order book visibility

• Core question(s):
• If a customer (Dr. Reddy’s) pauses API manufacturing, is there near-term disruption risk?
• Is FY28 $400m revenue supported by order book visibility?
• Management response:
• Says diverse customer base across Canada/India/MSAs/launches allows them to “pull demand into this quarter”.
• “don’t anticipate any impact on our supplies” and capacities are “full”.
• Order book visibility: “short answer… yes” with multiple pillars (DDC Canada approvals, India ~40% generic pens, biologics funnel, soft gel new customers, injectables capacity coming online).
• Assessment:
• Strong confidence language; however, “order book visibility” is asserted without providing hard metrics (e.g., backlog duration, conversion rates).

Theme D: DDC line fungibility, CSA vs MSA mix, and batch-size approvals

• Core question(s):
• Can customers be shifted between lines? Who decides?
• Does increasing batch size require resubmission?
• How does mix change (MSA vs CSA) with new capacity?
• Management response:
• Lines are designed to be fungible; customers can be serviced from both lines.
• Batch size increase: “should be possible… in most geographies” (market-dependent).
• Mix: management states capacity constraint previously limited onboarding; now they can add customers and expect “significantly more commercial sales than MSAs” (and “lines are driven by the CSA”).
• Assessment:
• Helpful operational detail; still avoids jurisdiction-specific regulatory certainty (uses “should be possible”).

Theme E: FY27 milestones to ensure FY28 delivery

• Core question(s):
• What investors should monitor over remaining FY27 quarters to confirm on-track status?
• Management response:
• Track capacity additions (new line this quarter; next expansion toward end of year).
• Watch sequential ramp in H2 as new line impacts revenues/EBITDA.
• Emphasizes “strong visibility on order book and capacity utilization”.
• Assessment:
• No new quantitative checkpoints; relies on qualitative “visibility”.

Theme F: Biologics contract timing, value chain, and competitive risk

• Core question(s):
• When do biologics contracts contribute? Any dedicated capacity?
• Are they R&D/DS/DP integrated or primarily CMO?
• Does domestic competition entering biologics CDMO pose a risk?
• Management response:
• Contracts contribute beyond FY28 commercially; near-term is development/MSA revenues, commercialization “FY29 and beyond”.
• They position as “completely integrated drug substance and drug product… from a gene to the final product”.
• Competitive risk reframed as opportunity: India’s share is “insignificant” vs South Korea; demand growth and guideline changes support capacity expansion.
• Assessment:
• Strong narrative; avoids discussing specific contract economics (size, margins, conversion probability).

Theme G: Capex outlook

• Core question(s):
• Capex for FY27 and FY28 including expansions.
• Management response:
• Of the “roughly last year… US$100 million capex”, “almost 80%… committed”.
• “for this year, no significant capex” beyond remaining ~20% balance; additional biologics capex expected but “significantly lower” than DDC.
• Assessment:
• Clear directional guidance; still no exact FY27 capex number.

4. Guidance / Outlook

Explicit guidance (quantitative)

• FY28 organic revenue: “$400 million organic revenue”
• FY28 EBITDA margin: “EBITDA margins of 40%”
• FY28 outlook reiterated (no change vs prior calls in this transcript set).

Implicit signals (qualitative)

• Capacity-driven ramp: sequential Q/Q improvement expected as new sterile line comes online.
• Demand confidence: “order book… very clear”, “capacities are full”.
• Beyond FY28 growth: management expects EBITDA trajectory to “continue to go upward beyond FY28” driven by:
• biologics commercialization “FY29 and beyond”
• soft gel capacity filling
• injectable new capabilities
• drug-device long “legs” as Europe/US open up.

5. Standout Statements (direct / high-signal)

• Canada semaglutide execution: “all three approvals… are with us” and “two of our partners… have already launched.”
• Supply constraint mitigation: “despite the temporary disruption in supplies… our available capacities are full.”
• Capacity impact: “second cartridge line being set for commercialization in this quarter” and “will double our number of sterile days.”
• Customer onboarding unlock: “we’ve been saying we’re not been able to add new customers because of supply gap. Now… we would be adding customers.”
• Biologics pipeline acceleration: “pipeline… almost 4x of what it was just over a year ago” and “strongest ever.”
• FY28 reaffirmation: “remain confident… reiterate our FY28 outlook of $400 million organic revenue… EBITDA margins of 40%.”
• Soft gel conversion timeline: “capacity… completely taken over the next 12 to 15 odd months.”
• Operational fungibility: “lines… should be able to cater to all our customers… capacities are fungible.”
• Geopolitics impact framing: “our impact is fairly muted… because… ex-works contracts.”

6. Red Flags / Positive Signals

Positive signals
– Strong operational execution claims: approvals, launches, inspections.
– Clear capacity-to-demand linkage: “capacities full”, “order book visibility yes”.
– Compliance credibility reinforced with FDA surprise audits.

Red flags / uncertainties
– Soft gel revenue lag despite major capacity increase—management attributes to tech transfer timing, but this is a recurring “conversion takes time” theme that can delay revenue realization.
– Limited quantitative disclosure in Q&A:
– No hard backlog/order book numbers, conversion rates, or segment-wise utilization percentages.
– Margin bridge largely qualitative (mix/seasonality).
– Regulatory/batch-size approvals: “should be possible” and “market to market” language implies execution risk.
– Shutdown timing: shutdown starts Q1 and spans Q2/Q3—yet management still projects strong FY28; investors may want more clarity on cost/impact.

7. Historical Comparison & Consistency Analysis (vs prior 3 calls)

a. Change in Tone Over Time

• Current (Q1 FY27): Optimistic
• Prior calls:
• Q4 FY26 (May 13, 2026): optimistic recovery narrative; reaffirmed FY28 guidance; emphasized Canada approvals and sequential improvement.
• Q2 FY26 (Nov 12, 2025): optimistic but included explicit caution that “numbers may not necessarily reflect the true nature of the work” due to regulatory ambiguity and revenue recognition uncertainty.
• Q1 FY26 (Aug 5, 2025): optimistic but framed H1 as “muted” and emphasized transition from MSA to commercial supplies.
• Shift classification: More Optimistic
• Current call is more confident on execution (“approvals with us”, “capacities full”, “order book visibility yes”) compared with earlier calls that highlighted ambiguity and revenue recognition uncertainty.

b. Tracking Past Commitments vs Outcomes

• Past statement (Q4 FY26, May 13, 2026): second DDC line “undergoing qualification… due for availability… next quarter.”
• Expected: commercialization impact in FY27.
• Current outcome (Q1 FY27): “second cartridge line being set for commercialization in this quarter” → ✅ On track (timing aligns with “next quarter” concept).
• Past statement (Q2 FY26, Nov 12, 2025): capacity expansion plan accelerated; “fully ready by end of calendar year ’26” and “stopped onboarding new DDC customers simply because we do not have the capacities.”
• Expected: easing of onboarding constraints as capacity comes online.
• Current outcome: management says onboarding constraints easing: “Now… we would be adding customers” → ✅ Partially delivered (capacity is coming online; soft gel still converting over 12–15 months).
• Past statement (Q2 FY26, Nov 12, 2025): biologics funnel “almost 4x” and long gestation; commercialization “beyond current time horizon” (FY29+).
• Current: biologics pipeline “almost 4x” again (similar metric) and Formycon contract added; commercialization still framed as FY29+ → ✅ Consistent (no contradiction).

c. Narrative Shifts

• Soft gel narrative changed from “capacity online” to “tech transfer conversion takes 12–15 months.”
• Earlier calls emphasized capacity build-out; current call admits revenue lag is operationally tied to CDMO transition.
• DDC narrative shifts from “ambiguity/revenue recognition uncertainty” to “approvals with us + capacities full + order book clear.”
• This is a meaningful credibility improvement in the semaglutide commercialization story.

d. Consistency & Credibility Signals

• Credibility: Medium-High
• Strengths: repeated reaffirmation of FY28 guidance; operational milestones (line qualification/commercialization) appear consistent.
• Weaknesses: recurring “timing/recognition” caveats in earlier calls; current call still avoids hard numbers (order book size, segment utilization, capex exacts), limiting verification.

e. Evolution of Key Themes

• Demand (semaglutide): Improving/stabilizing from “supply constraint” framing to “launch execution + partner launches + capacity full”.
• Margins: Improving sequentially; attributed to mix/seasonality rather than cost cuts—consistent with a capacity ramp story.
• Expansion: DDC capacity expansion now actively commercializing; biologics expansion framed as next leg; soft gel conversion still in progress.
• Risk management: Earlier calls emphasized regulatory ambiguity; current call emphasizes mitigation via diversified customer base and ex-works terms.

f. Additional Insights (cross-period intelligence)

• The company’s “capacity full” claim is now supported by multiple mechanisms (Canada approvals, India market share manufacturing, new line coming online), but soft gel shows that “capacity installed” ≠ “capacity monetized” immediately—suggesting investors should discount near-term revenue realization for newly converted CDMO platforms.
• Management’s confidence in FY28 appears to be increasingly anchored in DDC execution (Canada + India + new line) rather than broader modality optimism.